A global community of oncology pharmacy practitioners striving to advance cancer care Around the World: 24-Hour Virtual Symposium What to Expect With just 42 days to go until the Around the World: 24-Hour Virtual Symposium, I am delighted to share more detail about what the 24 hours will include, with you choosing when and how often you join.
The Symposium has been designed as a 24-hour experience to ensure members around the world—regardless of time zone—can participate in live sessions and networking opportunities.

Alongside the plenary sessions (outlined below), participants will have access to regular networking opportunities through themed roundtable discussions in breakout rooms. These sessions will take place during scheduled breaks, giving participants the flexibility to rest, stretch, or join a conversation. Topics will span professional interests—such as biosimilar implementation and getting started in research—as well as lighter and wellbeing-focused themes, including hobbies like canoeing or badminton (to get to know each other), and discussions on managing workload and burnout. These roundtables aim to foster meaningful connections, encourage collaboration, and expand your global professional network. The program will also feature 12 plenary presentations, showcasing the highest-rated abstracts across four different time zones—highlighting the best of ISOPP’s global expertise.
Registration is just 30 CAD, making this an accessible and sustainable learning opportunity for members worldwide.
 

We encourage you to register and to share this event with colleagues on line and on socials. Your support will be instrumental in ensuring success. #ISOPP2026.
  Program* highlights include:
    *subject to change We look forward to welcoming you online for this truly global Symposium.  

Patient-centric strategies in ER-positive/HER2-negative MBC
Education Alert
Communicating to Enhance Care Through Data and Patient Experience: ER-Positive/HER2-Negative Metastatic Breast Cancer Edition
0.50 CME / CE / ABIM MOC
Did you know that benefits of transitioning from fulvestrant to oral SERDs are fewer clinic visits and more patient independence?

Education Alert
Assessing Conditioning Regimens for HSCT: Optimizing Patient Outcomes
30 min EBAC
Experts discuss currently used conditioning regimens and upcoming antibody-based regimens for patients with AML and MDS.

Bladder Cancer Treatment Updates

Even though 75% to 85% of the 83,000 annual US bladder cancer cases are non–muscle invasive bladder cancer (NMIBC), safe and effective treatment options remain limited, and many patients need novel solutions.
Stay up to date on the latest advances in bladder cancer treatment with this brief CME activity. Explore key insights from AUA and ASCO 2025, including new clinical trial data and emerging therapies. Designed for oncologists and the entire multidisciplinary care team, this activity helps you navigate the evolving clinical landscape and apply the most current evidence to practice.

Faculty Matthew Galsky, MD   Professor of Medicine (Hematology and Medical Oncology)   Director of Genitourinary Medical Oncology   Co-Director of the Center of Excellence for Bladder Cancer Associate Director for Translational Research The Tisch Cancer Institute  Mount Sinai School of Medicine  New York, NY

Expiring Soon! On-Demand CE on SGLT-2 Inhibitors This educational activity will provide an overview of CKM syndrome and evidence supporting early screening and treatment. The latest data from all landmark clinical trials, systematic reviews, and meta-analyses demonstrating the benefit of SGLT2 inhibitors on cardiorenal outcomes and clinical trials currently underway to identify potential emerging areas for SGLT2 inhibitor benefit will be presented. A review of the latest clinical practice guidelines for the use of SGLT2 inhibitors in heart failure, kidney disease, and diabetes will be shared. The activity will conclude with an exploration of interprofessional care models that address barriers and incorporate pharmacists into the initiation, titration, and monitoring of SGLT2 inhibitor therapy for patients who could benefit from treatment.  We invite you to share this free educational activity with your colleagues.  PharmD, MPH, BCCP
Activity Chair    Clinical Pharmacy Specialist
Brigham and Women’s Hospital
Boston, Massachusetts PharmD, CDCES, FAPhA, FADCES    Director of Experiential Education, Professor in Pharmacy Practice – Midwestern University College of Pharmacy, Downers Grove, IL
Diabetes Care & Education Specialist – Bolingbrook Christian Health Center
Bolingbrook, Illinois This activity was planned to meet the educational needs of pharmacists who practice in hospitals, health systems, community pharmacies, and ambulatory clinics who care for or are interested in the care of patients who have type 2 diabetes, heart failure, and/or chronic kidney disease. Welcome and Introductions
Leo F. Buckley
  The Heart of it All: Identifying People Who May Benefit from SGLT2 Inhibitor Treatment  Leo F. Buckley
  Filtering the Evidence: Designing Individualized SGLT2 Inhibitor Treatment Plans for People with T2D, HF, and/or CKD Based on Guidelines and Evidence-Based Practices  Susan Cornell
  Putting It into Practice (Case-based Examples): Interprofessional Care Models for the Initiation and Optimization of Therapy in People with T2D, HF, and/or CKD  All Faculty
  Faculty Discussion, Questions and Answers All Faculty   ACPE #: 0204-0000-24-406-H01-P CE Credit: 1.5 contact hours (0.15 CEUs) Activity Type: Application-based Activity Fee: No charge  Available: February 13, 2025 - February 13, 2026
To receive CE credit, complete the steps below within 60 days of completing the activity. After the 60-day deadline, ASHP will no longer be able to report credits(s).

Updates in Skin Cancer & Melanoma

FDA Receives Pre-Market Approval Module for Novel Recurrent CSCC Therapy

Frontline Sorafenib Shows Promising Outcomes in Metastatic Uveal Melanoma

Melphalan/Hepatic Delivery System Displays Efficacy in Uveal Melanoma

 

Do you know when to use surgery and/or systemic treatment when managing neurofibromatosis type 1 (NF1)-associated plexiform neurofibromas (PN)s?
Education Alert
Optimizing Management of NF1-Associated Plexiform Neurofibromas: Expert Multidisciplinary Team Discussions
0.50 CPD
Experts discuss what you need to know to support your NF1-associated PNs patients.

Epcoritamab Enhances Progression-Free Survival vs SOC in R/R DLBCL


NCCN Thermometer Detects High Psychological Distress in Breast Cancer


NEW VIDEO
How to elevate multidisciplinary care in pancreatic cancer?



Videos
Optimizing Cellular Therapy Use Across All Stages of Multiple Myeloma













Trending

Taiwan FDA Approves Nivolumab/Ipilimumab for MSI-H/dMMR Metastatic CRC